These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17151146)

  • 1. The costs of drugs for schizophrenia.
    Freedman R; Carpenter WT; Davis JM; Goldman HH; Tamminga CA; Thomas M
    Am J Psychiatry; 2006 Dec; 163(12):2029-31. PubMed ID: 17151146
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).
    Lieberman JA
    Arch Gen Psychiatry; 2006 Oct; 63(10):1069-72. PubMed ID: 17015808
    [No Abstract]   [Full Text] [Related]  

  • 3. Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Rosenheck RA
    Arch Gen Psychiatry; 2006 Oct; 63(10):1074-6. PubMed ID: 17015809
    [No Abstract]   [Full Text] [Related]  

  • 4. Lessons from each drug trial.
    Marder SR
    Am J Psychiatry; 2007 Mar; 164(3):375-6. PubMed ID: 17329457
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
    Rosenheck RA; Leslie DL; Sindelar J; Miller EA; Lin H; Stroup TS; McEvoy J; Davis SM; Keefe RS; Swartz M; Perkins DO; Hsiao JK; Lieberman J;
    Am J Psychiatry; 2006 Dec; 163(12):2080-9. PubMed ID: 17151158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NIMH-CATIE Schizophrenia Study: what did we learn?
    Lieberman JA; Stroup TS
    Am J Psychiatry; 2011 Aug; 168(8):770-5. PubMed ID: 21813492
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of schizophrenia pharmacotherapy.
    Soumerai SB; Law MR
    Am J Psychiatry; 2007 Apr; 164(4):678; author reply 678-9. PubMed ID: 17403984
    [No Abstract]   [Full Text] [Related]  

  • 8. Iloperidone for the treatment of schizophrenia: an updated clinical review.
    Weiden PJ
    Clin Schizophr Relat Psychoses; 2012 Apr; 6(1):34-44. PubMed ID: 22453868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia.
    Nasrallah HA; Tandon R
    J Clin Psychiatry; 2002; 63 Suppl 13():12-20. PubMed ID: 12562142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract]   [Full Text] [Related]  

  • 11. The CATIE study.
    Basil B; Mathews M; Adetunji B; Budur K
    Am J Psychiatry; 2006 Mar; 163(3):555; author reply 555-6. PubMed ID: 16513895
    [No Abstract]   [Full Text] [Related]  

  • 12. Adjunctive versus monotherapeutic treatment for schizophrenia: addressing antipsychotic side effects.
    Hazra M; Mamo DC; Remington G
    Am J Psychiatry; 2008 Mar; 165(3):396-7; author reply 397-8. PubMed ID: 18316434
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacoeconomic factors related to the treatment of schizophrenia. Concluding discussion.
    J Clin Psychiatry; 1999; 60 Suppl 3():59-60. PubMed ID: 10073380
    [No Abstract]   [Full Text] [Related]  

  • 14. Tardive dyskinesia circa 2006.
    Kane JM
    Am J Psychiatry; 2006 Aug; 163(8):1316-8. PubMed ID: 16877639
    [No Abstract]   [Full Text] [Related]  

  • 15. First- and second-generation antipsychotics: learning from CUtLASS and CATIE.
    Tandon R; Carpenter WT; Davis JM
    Arch Gen Psychiatry; 2007 Aug; 64(8):977-8; author reply 979-80. PubMed ID: 17679642
    [No Abstract]   [Full Text] [Related]  

  • 16. All antipsychotics are equal, but some are more equal than others.
    Volavka J; Citrome L
    J Clin Psychiatry; 2009 Mar; 70(3):429-30. PubMed ID: 19317959
    [No Abstract]   [Full Text] [Related]  

  • 17. Neurotensin receptor agonists and antagonists for schizophrenia.
    Robertson VB; Wilson MS
    Am J Psychiatry; 2005 Mar; 162(3):634; author reply 635. PubMed ID: 15741502
    [No Abstract]   [Full Text] [Related]  

  • 18. Great(er) expectations.
    Lauriello J
    Am J Psychiatry; 2007 Mar; 164(3):377-9. PubMed ID: 17329458
    [No Abstract]   [Full Text] [Related]  

  • 19. Relationship between costs and symptoms in schizophrenia patients treated with antipsychotic medication: a review.
    Sevy S; Visweswaraiah H; Mentschel C; Leucht S; Schooler NR
    J Clin Psychiatry; 2004 Jun; 65(6):756-65. PubMed ID: 15291652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of chronic psychotic ambulatory outpatients.
    Petty RG
    J Clin Psychiatry; 1998; 59 Suppl 19():30-5. PubMed ID: 9847050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.